| Description: |
Edralbrutinib (TG-1701) is a potent, novel, orally active, irreversible BTK inhibitor that selectively inhibits the activation, proliferation, and survival of B cells, and can act on other immune cells, such as macrophages, to influence the autoimmune inflammatory process mediated by B cells and other immune cells, and can be used in the study of optic neuromyelitis optica spectrum disorders (NMOSD). |
| Stability and Solubility Advice: |
Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide.
We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials and used within 1 month. Avoid repeated freeze and thaw cycles. Storage conditions for some special products should refer to their storage details. |
